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The establishment of the two distinct lineages that form the branched 
epithelial ductal tree of the mammary gland is a complex and essential 
developmental process. Two independent studies now describe the switch 
from multipotency to unipotency as an embryonic process and outline 
mechanisms of early lineage restriction. 
 
Embryonic mammary epithelial cells (MECs) are a unique cell population 
comprised of undifferentiated and highly plastic progenitor cells that ultimately 
give rise to all postnatal MECs1,2. Lineage tracing studies have previously 
indicated that embryonic mouse mammary cells are multipotent in vivo1. Like 
other organs, mammary glands form during prenatal growth and continue to 
develop after birth from the descendants of these multipotent prenatal 
mammary cells. The rudimentary branched epithelium of the mammary gland 
present at birth holds the capacity for rapid ductal development (puberty), milk 
production (lactogenesis) and regeneration (involution), processes that are 
enabled by epithelial cellular plasticity and lineage restriction. The two 
principal lineages of the mammary gland consist of basal cells with contractile 
muscle and epithelial properties that determine the basal membrane and 
encapsulate the ductal-facing luminal cells2,3.  Luminal cells are polarised and 
consist of estrogen receptor positive (ER+) or negative (ER-) ductal cells and 
secretory ER- alveolar cells3. During normal tissue homeostasis, these two 
lineages are maintained predominantly by lineage-restricted stem cells, but 
when lineage restriction of multipotent mammary cells occurs had not been 
fully elucidated.  
In this issue of Nature Cell Biology, Lilja et al.4 and Wuidart et al.5 examine 
the switch of multipotent stem/progenitor cells to unipotency (Fig.1a). 
Utilising the multi-colour Confetti reporter mouse and clonal analysis during 
embryonic mammary gland development, they investigate the kinetics of 
stem and progenitor cells and both show that transition from multipotency to 
unipotency occurs surprisingly early during prenatal stages of development. 
The two manuscripts from the Blanpain and Fre laboratories arrive at similar 
conclusions using complimentary approaches. Each group also identifies a 
key complementary lineage-restricting regulator that is capable not only of 
driving embryonic mammary cells towards a single lineage, but also of 
reprogramming mature postnatal MECs to switch from one lineage to the 
other.  
Building on previous work demonstrating that Keratin 14 (K14) expressing 
cells of the embryonic mammary gland can develop into both basal and 
luminal lineages1, Wuidart et al. now further characterised the temporal switch 
from embryonic multipotency to lineage restriction. They associated 
multipotency with the simultaneous expression of basal and luminal hybrid 
gene signatures, and identified the transcription factor p63 as promoter of the 
basal lineage in multipotent progenitors5. p63 is a known regulator of epithelial 
transcriptional profiles and its accumulation in a Rbpj conditional knock-out 
mouse model induced a basal profile in luminal cells, which included K5 
expression6. 
 
Lilja et al. determined E15.5 as the embryonic timepoint when multipotent 
MECs become lineage restricted. The authors identified Notch1 as a potential 
marker of bipotency in the nascent mammary bud and an orchestrator of cell 
fate during late embryonic development, dictating progression towards ER- 
luminal progenitors4. Notch signalling is ubiquitous in higher eukaryotes and 
activated during stem cell maintenance and differentiation in a multitude of 
tissues7. Notch1 activation in mammary stem cells dictates luminal lineage 
selection and promotes luminal progenitor cell expansion, which has been 
associated with tumourgenesis7. 
 
Lilja et al. analysed Notch1 expressing cells in the embryonic mammary gland 
using a double fluorescent reporter line (N1CreERT2/R26mTmG), which revealed 
Notch1 receptor expression in the majority of cells of the mammary bud at 
E13.5 and E15.5. All Notch1 positive cells at the E13.5 stage were positive for 
K5, K14 and p63 basal markers, alongside the luminal marker K8. FACS 
analysis of the Notch1 positive progeny suggested that, at the population 
level, descendants of Notch1 positive cells labelled at this stage show no 
lineage bias. Wuidart et al. reached the same conclusion after analysing gene 
signatures of E14.0-stage Lgr5+ embryonic mammary progenitor cells that 
showed co-expression of basal and luminal markers. Progeny from K14+ cells 
labelled at E13.0 also showed no lineage bias. 
 
The single-cell RNA sequencing analysis performed by Wuidart et al. provided 
some tantalising insights into the signalling used by embryonic mammary 
progenitor cells at E14, which showed a hybrid, basal-luminal embryonic 
mammary progenitor gene signature during normal development. Bulk RNA 
sequencing of postnatal MECs indicated that luminal cells also went through a 
transient hybrid multipotent state after ΔNp63-induced cell fate reprograming 
into basal cells, as shown by Wuidart et al. The same was observed by Lilja et 
al. for basal cells that switched to a luminal fate after ectopic Notch1 
expression (Fig. 1b). However, single-cell RNA sequencing analysis of MECs 
has inherent caveats. It is not yet clear whether the removal of MECs from 
their microenvironment during the experimental process alters their gene 
signatures. Basal MECs harbour the ability to acquire a multipotent stem cell 
state without additional manipulation, after isolation from their niche within the 
mammary gland1. This potential limitation needs to be considered in all single-
cell analyses of mammary progenitor cells. Stem and progenitor cells are 
thought to exist in a spectrum of cell states and it is likely that other types of 
embryonic progenitor cells are present in addition to those described in the 
two manuscripts, for instance cells that do not express Lgr5 or Notch1. 
 
Both studies implicate cell-autonomous processes in the initiation of a 
mammary cell progenitor state. A number of classic tissue recombination 
studies, in which embryonic epithelial and mesenchymal (embryonic stroma) 
tissues from heterotypic organs are separated, recombined, and allowed to 
develop in organotypic culture, have shown that non-cell autonomous signals 
from the embryonic mammary mesenchyme are instructive and can confer 
mammary cell identity to non-mammary epithelium, even across species8. It is 
unclear which stromal factors are involved in mammary induction and these 
types of experiments have not yet been subjected to rigorous modern 
molecular analyses. It will be interesting to see how the molecular signatures 
of embryonic cells that have initially been specified via mammary tissue 
interactions compare to the signatures of multipotent embryonic mammary 
progenitors and postnatal MECs undergoing cell fate specification described 
in these two studies. As of yet, no clear-cut markers exist to discern 
embryonic MEC identity from other embryonic epithelial organs and 
unambiguously show that a cell has committed completely to an embryonic 
mammary fate. 
 
Plasticity, defined as the ability of cells to dynamically change their state, is 
crucial for many processes during mammary gland development and tissue 
homeostasis. However, in breast cancer pathogenesis, dysregulated plasticity 
produces cellular heterogeneity and might complicate therapies, in particular 
as the disease progresses. Breast cancer treatments are routinely prescribed 
to patients based on the expression of a small number of key markers present 
in the primary tumour (ER, PR, HER2) and these marker profiles can be 
distinct from those expressed by disseminated lesions or recurrent 
disease9.  A better understanding of the reprogramming potential of postnatal 
cells and plasticity regulators may eventually lead to improvements in cell 
state manipulation and therapeutic approaches for breast cancers, including 
stem cell-based therapies. In addition, the contribution of rare multipotent cells 
to normal mammary gland development and homeostasis has been debated, 
and their physiological function remains unclear2. 
 
The reactivation of embryonic programmes in adult cells has also been 
implicated in cancer10. Studies using mouse models of breast cancer report 
that PIK3CA mutations disrupt lineage restrictions of luminal and basal 
progenitor cells11,12, suggesting that a gain of multipotency, a unique feature 
of embryonic mammary progenitor cells, may be a common occurrence in 
breast cancer. In support of this notion, SOX11, a transcription factor highly 
expressed by embryonic mammary progenitor cells, including those profiled 
by Wuidart et al., is not expressed in the normal postnatal breast, but 
upregulated in aggressive breast cancers, including triple negative and 
HER2+ sub-types10. SOX11 is also expressed in ER- and HER2+ pre-
invasive ductal carcinoma in situ lesions and promotes invasive growth in both 
3D in vitro assays and mouse models of these lesions13. Taken together, 
these findings raise the questions of whether MEC lineage restriction 
represents a tumour suppressive mechanism and whether reactivation of 
multipotency is a crucial step in breast cancer initiation. Stemness features 
are associated with oncogenic dedifferentiation across multiple cancer types, 
and have been put forward as a hallmark of cancer14. 
 
Finally, the regulation of the prenatal to postnatal shift in mammary plasticity 
might also be an important subject for further study. In epithelial tissues, p63 
is regulated by the epigenetic regulator KMT2D (MLL4) in a genome-wide 
manner15, which suggests the Notch1-p63 axis postulated by these papers 
could be part of an epigenetic switch during development. MECs harbor 
reprogramming potential that is realised during breast tumourigenesis. What 
are the signals that reactivate multipotency? Identifying the key regulators of 
mammary epithelial plasticity will reveal basic mechanisms underlying tissue-
specific stem cell behaviour, which could lead to the development of targeted 
approaches to expand breast cancer prevention and therapeutic options.  
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Figure Legends 
 
Figure 1. Schematic representation of embryonic bifurcation of the 
mammary lineage and reprogramming of mammary epithelial cells after 
lineage restriction. 
a) Prenatal lineage restriction of multipotent embryonic mammary 
epithelial cells. Multipotent mammary progenitor/stem cells exist in the 
embryonic mammary gland at mid-gestation and give rise to unipotent basal 
and luminal progenitor cells prior to birth. Multipotent mammary 
progenitor/stem cells co-express markers from the basal and luminal lineages. 
Embryonic mammary progenitor cells become biased towards one lineage as 
development proceeds and adopt marker profiles and location within the 
epithelium accordingly.  
b) In vivo reprogramming of postnatal mammary epithelial cells. 
Mammary epithelial cells (MECs) in the postnatal mammary glad are 
unipotent. Both luminal and basal (myoepithelial) cells can be reprogrammed 
to switch lineage by p63 and Notch1, respectively, after passing through an 
intermediate state similar to that found in multipotent mammary 
stem/progenitor cells that are abundant in the early stages of embryonic 
mammary gland development.  
 
 
 
 
 
